Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.710 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors 
From Recursion Pharmaceuticals
Via GlobeNewswire
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
Via The Motley Fool
Topics Bankruptcy Economy World Trade
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Why Recursion Pharmaceuticals Stock Is Sinking Today
Via The Motley Fool
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
Via The Motley Fool
Topics Government World Trade
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Nvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI Stocks
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Jim Cramer: Fiserv Is 'One Of The Greatest Fintechs,' Calls This Tech Company A Meme Stock
Fiserv recently completed its acquisition of Payfare Inc. On "Mad Money Lightning Round," Jim Cramer called it "one of the greatest fintechs." 
Via Benzinga
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy. 
From Recursion Pharmaceuticals
Via GlobeNewswire
Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?
Via The Motley Fool
Topics Artificial Intelligence
Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip
Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX. 
Via Benzinga
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today
Via The Motley Fool
This Biotech Stock Could Be the Best Investment of the Decade
The term "game-changing" is overused for too many up-and-coming companies, but in this case, the description fits. 
Via The Motley Fool
Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?
Via The Motley Fool
Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says
Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future revenue, according to Needham. 
Via Benzinga
Recursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The Dip
Leerink cited concerns over high cash burn and execution risks in deal-making and clinical development over the next year. 
Via Stocktwits
Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This Friday
Ark Invest made notable trades on Feb. 28, 2025. They purchased shares in ACHR, RXRX, TEM, and IRDM, while selling shares in TWST, ADYEY, ACCD, and EXAS. 
Via Benzinga
Topics Artificial Intelligence
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Earnings Scheduled For February 28, 2025
 
Via Benzinga
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
Company to host public (L)earnings call on February 28th at 8:30 am ET / 6:30 am MT / 1:30 pm GMT 
From Recursion Pharmaceuticals
Via GlobeNewswire
Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?
Recursion Pharmaceuticals' stock has soared due to Nvidia's continued investment, positioning the company as a leader in AI-driven drug discovery. 
Via MarketBeat
Topics Artificial Intelligence Regulatory Compliance
SoundHound and Serve Robotics Are Dropping Like a Rock -- Why Nvidia Was the Catalyst
Nvidia sold their stake in some high-flying stocks recently. 
Via The Motley Fool
Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City
The Altitude Lab Fund aims to deliver strong returns to Limited Partners, accelerate the growth of Salt Lake City’s Life Science hub, and enable high potential startups support while federal funding is... 
From Recursion Pharmaceuticals
Via GlobeNewswire
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
25 Top AI Stocks That Could Boost Your Portfolio
Via The Motley Fool
Topics Artificial Intelligence
Altitude Lab Startups Raise $154M in Capital
The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones 
From Recursion Pharmaceuticals
Via GlobeNewswire
SoftBank Joins Nvidia In Backing Recursion Pharma, Retail Traders Rally Behind Stock Surge
The Japanese conglomerate’s bet comes amid growing AI sector momentum, fueled in part by chipmaking giant Nvidia, which also holds over 7.7 million Recursion shares. 
Via Stocktwits
Topics Artificial Intelligence
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%) 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Why Recursion Pharmaceuticals Stock Is Soaring Today
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.